SCHEMBL6403175

SCHEMBL6403175

COc1ccc(NS(=O)(=O)CN(CCCc2ccccc2)C(=O)OC(C)(C)C)cc1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
L3MBTL1 Q9Y468 2/20 0.45
MMP3 P08254 3/20 0.45
MMP1 P03956 2/20 0.43
MMP2 P08253 2/20 0.43
PDE4A P27815 2/20 0.43
PDE4B Q07343 2/20 0.43
PDE4C Q08493 2/20 0.43
PDE4D Q08499 2/20 0.43
ALOX5 P09917 1/20 0.43
BMP1 P13497 2/20 0.42
LIMK2 P53671 1/20 0.42
ALDH1A1 P00352 4/20 0.42
SMN1; SMN2 Q16637 2/20 0.41
LMNA P02545 1/20 0.41
PTPRC P08575 1/20 0.41
PTPN2 P17706 1/20 0.41
PTPN1 P18031 1/20 0.41
PTPRB P23467 1/20 0.41
PTPRG P23470 1/20 0.41
ACP1 P24666 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6403170 0.90 TRPV1 (0.42) L3MBTL1LIMK2ALDH1A1SMN1; SMN2PTPRC
SCHEMBL6401373 0.88 MMP3 (0.40) L3MBTL1MMP3MMP1MMP2PDE4A
SCHEMBL6409447 0.81 ALDH1A1 (0.45) ALDH1A1SMN1; SMN2LMNAMAPTRAB9A
SCHEMBL6401375 0.81 NPC1 (0.39) MMP3MMP1MMP2PDE4APDE4B
SCHEMBL6407165 0.79 CA1 (0.40) MMP3MMP1MMP2PDE4APDE4B
SCHEMBL6404808 0.78 CASR (0.37) MMP3MMP1MMP2PDE4APDE4B
SCHEMBL6403266 0.78 L3MBTL1 (0.43) L3MBTL1ALOX5LMNARAB9A
SCHEMBL6409464 0.78 ALOX5 (0.42) L3MBTL1MMP3MMP1MMP2PDE4A
SCHEMBL6407189 0.78 MMP3 (0.41) MMP3MMP1MMP2PDE4APDE4B
SCHEMBL6403176 0.77 LPAR1 (0.45) MMP3MMP1MMP2PDE4APDE4B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6900237-B2 Sulfonamide compounds as protease inhibitors AXYS PHARMACEUTICALS, INC. (US) 2005-05-31 US disclosed
US-6841240-B2 Plastic material which exhibits high IR reflection and a high gloss is disclosed. The article includes at least three layers A, B and C, wherein layer A contains a transparent thermoplastic plastics material, and wherein layer B contains BAYER AKTIENGESELLSCHAFT (DE) 2005-01-11 US disclosed
US-20030158231-A1 Sulfonamide compounds as protease inhibitors Celera Corporation 2003-08-21 US disclosed
US-20030148093-A1 Plastic material which exhibits high IR reflection and a high gloss is disclosed. The article includes at least three layers A, B and C, wherein layer A contains a transparent thermoplastic plastics material, and wherein layer B contains BAYER AKTIENGESELLSCHAFT (DE) 2003-08-07 US disclosed
WO-2003024923-A1 SULFONAMIDE COMPOUNDS AS PROTEASE INHIBITORS AXYS PHARMACEUTICALS, INC. (US) 2003-03-27 WO disclosed
US-4044019-A STABILIZERS CIBA-GEIGY CORPORATION (US) 1977-08-23 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030158231-A1 Sulfonamide compounds as protease inhibitors PRSS1, PRSS3, SPINT2 L3MBTL1 4162/4885MMP3 66/4885MMP1 288/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.